



DKSH Q3 2023 Analyst and Investor Presentation

Stephen Ferraby, Head Corporate Affairs & Strategic Investments and Non-Independent Non-Executive Chairman, DKSH Malaysia


November 23, 2023

Delivering Growth – in Asia and Beyond.



Celebrating a Century of Enriching People's Lives









- **1.** About DKSH Group
- **2.** DKSH Malaysia at a Glance
- 3. Q3 2023 Results
- 4. Outlook



About DKSH Group

Who We Are



Your Trusted Partner

We enrich people's lives by providing access to goods, services, and insights. United by our vision to be the trusted partner, we help companies grow.



DKSH Is a Successful Market Leader











>10 years
4 markets

average client relationship¹

21.8 million transactions per year

We Support Companies to Grow Their Business...





We ensure that our clients' products are visible at all times.


- Helping companies to grow their business in new and existing markets
- Providing business partners with the knowledge, advice, relationships, and on-the-ground logistics to reach their individual growth goals
- Expanding their access to knowledge, their sourcing base, revenue opportunities, and ultimately, their market shares

This is what we define as **Market Expansion Services.**

...With a Comprehensive, Tailor-Made Portfolio of Services

DKSH

Market Expansion Services goes beyond offering individual services – it is about the integration of many different services to meet the needs of business partners





2 DKSH Malaysia at a Glance

DKSH Malaysia at a Glance





Celebrating 100 Years in Malaysia

Three Specialized Business Segments





Food Services

• Others – overheads

...leading the Market Expansion Services industry with tailored solutions across the value chain

Consumer Goods Segment





Fast Moving Consumer Goods (FMCG)

- Food (Nutritional products, snacks, beverages, dairy etc)
- Non-food (Personal care, home care, baby and child care, consumer health etc)
- Pet care

Food Services

• Provide customers high quality ingredients and the latest industry innovations from our world-class clients



New FMCG Partnerships







DKSH Malaysia appointed by Grand Universal Trading Sdn. Bhd. as the official and exclusive distributor for the tissue brands Paseo, Nice, and Livi in Malaysia. DKSH Malaysia appointed as the official distributor for Hill's Pet Nutrition Asia Limited's products, including its Prescription Diet and Science Diet lines for cats and dogs, in Malaysia.

Healthcare Segment



Healthcare

- Pharmaceuticals
- OTC & Consumer Health
- Medical Devices



New HEC Partnerships





As of Q3 2023, we have been appointed by the following healthcare business partners to grow their businesses in Malaysia:

- Mundipharma (OTC)
- Alcon
- Becton Dickinson (BD)
- Korean Ginseng Corp
- Embecta
- Organon

Others Segment





At the end of FY2022, there were a total of 86 outlets located in West and East Malaysia as well as two outlets in Brunei

Brand Collaboration: January – June 2023

Famous Amos remains actively engaged in collaborations with various brands to create delightful treats for Malaysians and to amplify our brand presence.

Our recent partnerships include Krispy Kreme, Madam Croffle, and Eureka Popcorn. Additionally, we have extended our presence to KidZania Kuala Lumpur, an award-winning family-themed learning center.





Serving International Clients...



Trusted Partner for Well-Known International Brands Consumer Goods: Schick PICKUPI Wyeth Nutrition The Star of All Natural Goatness Bahlson (Enfaarow/ HEINZ SUSTAGEN' Intuition S26 TWININGS OFFER nutella nutella Bready Kinder FERRERO Dr.Oetker nona Post Wattien tac McCain dairylea Happ EMBORG arlsberg HERE Nando's (KOTANYI) Creeniee Cadbury PHILADELPHIA WRIGLEY whiskas CUSTARD Extraoss Milna Beiersdorf BANANA BOAT. **Healthcare:** Alcon Pharmanovia BAYER UNOVARTIS SANDOZ SONOFI KAOS Medtronic STADA Mölnlvcke LaCorium wipro Meristol Myers Squibb Celgene Beiersdorf Reche Diagnostics Celgene Beiersdorf Celgene Celgene Beiersdorf Celgene Ce нитап Liva Nova Health Innovation that matters B torrent **KALBE BD Brill** international **b** convotec Juniper Biologics a_x×essbio PHARMA The Roval College of Pathologists of Australa CooperVision Gynoflor[®] AQUA^{*} ¹⁰ MARIS MINARIS A Trinity Biotech inmunotek mindray Merislon Myonal Fluomizin® GLUTANEX SPLAT Hiruscar Janssen 🔽 🐇 ORGANON stryker 🔁 Abbott (อาหาอน) EUCOGEN karo pharma & mundi pharma PopoMama

...and Local Brands









Q3 2023 Results



| Financials | | | |
|---------------------------------------|---------|---------|----------|
| (in RM millions) | Q3 2023 | Q3 2022 | Change % |
| Revenue | 1,808.9 | 1,829.7 | (1.1)% |
| Profit before interest and tax | 27.4 | 30.6 | (10.4%) |
| Profit before tax | 20.8 | 23.7 | (12.3%) |
| Profit after tax | 17.4 | 17.7 | (1.7%) |
| (in RM sen) | | | |
| Earnings per share (EPS) | 11.0 | 11.2 | (1.7%) |
| Cash earnings per share (Cash EPS) | 14.9 | 15.2 | (1.9%) |

Comments

- Revenue declined due to nonrecurring hospital tender, offset by the following:
 - ✓ Sales from new clients and strong growth from existing clients in Healthcare segments
 - ✓ Higher outlet sales in Others segment with resumption of batter supply
 - ✓ Relatively stable sales in Consumer Goods segment
- Profit before tax declined due to higher operating expenses and lower net derivative gains
- Healthcare Segment continues to experience growth
- Short-term challenges are observed in the Consumer Goods Segment due to price increases in Fast-Moving Consumer Goods (FMCG) products, impacting overall volume

Revenue balanced by stable CG sales and improved growth in HEC and Others segment

FMCG

Food Services

2

Consumer Goods Segment



| Fi | nancials | | |
|--|----------|---------|----------|
| (in RM millions) | Q3 2023 | Q3 2022 | Change % |
| Revenue | 967.8 | 964.1 | 0.4% |
| Segment profit before interest and tax | 10.9 | 19.4 | (43.5%) |

Comments

- Revenue growth reflects stable sales
- Segment profit declined due to change in sales mix as well as higher personnel and logistics costs
- Impacted by MYR 4.5 million relative movement in provision for debt
- Despite the decline in segment profit, gross margin has improved

Change in sales mix and higher personnel and logistics costs impacted operating result

Healthcare Segment



| Fi | nancials | | |
|--|----------|---------|----------|
| (in RM millions) | Q3 2023 | Q3 2022 | Change % |
| Revenue | 820.5 | 854.3 | (3.9%) |
| Segment profit before interest and tax | 17.5 | 15.0 | 16.7% |

Comments

- Revenue declined by 3.9% due to nonrecurring hospital tender, offset by sales from new clients and strong growth from existing clients
- Segment profit improvement of 16.7% driven by improved margin mix



Improved margin mix led to better operating result

Others Segment



| Fi | nancials | | |
|--|----------|---------|----------|
| (in RM millions) | Q3 2023 | Q3 2022 | Change % |
| Revenue | 20.6 | 11.3 | 82.7% |
| Segment profit before interest and tax | (1.0) | (3.7) | 73.4% |

Comments

- Revenue grew 82.7% from the resumption of batter supply
- Segment profit improved by 73.4% due to strong sales

1 Famous Amos



Revenue improved due to resumption of batter supply

Cash Flows



| Financials | | |
|---|---------|---------|
| (in RM millions) | Q3 2023 | Q3 2022 |
| Net cash flows used in operating activities | (126.4) | (27.1) |
| Net cash flows used in investing activities | (9.0) | (25.8) |
| Net cash flows from financing activities | 137.2 | 34.8 |
| Cash and cash equivalents | 37.7 | 91.5 |

Comments

- Higher cash flows used in operating activities due to higher inventory balances from increased stock holding to cater for future sales in Healthcare
- Lower cash outflows in investing activities due to PY acquisition of AcuTest of RM18.5m
- In financing activities, higher short-term borrowings to fund working capital

Increase in working capital to support existing and future growth





Outlook

• This year, DKSH celebrates 100 years of presence in Malaysia.

- Overall, consumer demand remains largely stable with the easing of inflationary pressures and future growth is promising
- Continue to prioritize in gaining new businesses, increasing cost efficiency, managing working capital, and continuously monitoring of the short-term outlook.

With a well diversified portfolio, the Group is well positioned to benefit from favorable long-term market, industry, and consolidation trends in Asia Pacific



Two market trends...



1 Growing middle class in Malaysia

2 Trend towards outsourcing

Increased spending on value-for-money consumer goods and healthcare products

Investments in local infrastructure and industries

...boost expansion, consumer/industrial spending as well as MES industry





We welcome your questions



Thank you for your attention



Delivering Growth - in Asia and Beyond.